Bendectin (Pyridoxine/Doxylamine) Litigation Lawsuit

Bendectin (Pyridoxine/Doxylamine) Litigation

Bendectin was a prescription anti-nausea drug used by pregnant women in the United States for decades, and it became the subject of one of the longest-running product liability disputes in the country. Hundreds of families sued the manufacturer alleging that the drug caused birth defects, claims the company and subsequent scientific studies disputed. The dispute is also remembered for its effect on the rules of evidence: the litigation produced a Supreme Court decision that reshaped how federal courts admit expert testimony.

Product and manufacturer

Bendectin combined pyridoxine (vitamin B6) with doxylamine succinate, an antihistamine, and was marketed for nausea and vomiting of pregnancy. It was first introduced to the U.S. market in 1956 as a three-ingredient formulation that also included dicyclomine; that ingredient was dropped from the formulation in 1976, leaving the two-drug combination. The company that marketed the product, Merrell Dow Pharmaceuticals, removed it from the U.S. market in 1983.

The alleged defect and the harm

The claims against Bendectin centered on pregnancy outcomes. Plaintiffs alleged that the drug caused a range of fetal malformations, including limb and other musculoskeletal deformities, facial and brain damage, and defects of the respiratory, gastrointestinal, cardiovascular, and genital-urinary systems. The manufacturer denied the causal link. Epidemiological work did not support the allegations: multiple meta-analyses of studies covering more than 200,000 exposed pregnancies found no increased risk of major malformations, and a panel of Canadian and American experts concluded the combination was not a teratogen. A U.S. Food and Drug Administration panel likewise concluded that no association between Bendectin and birth defects had been demonstrated.

Litigation

Despite the scientific record, a large volume of individual product-liability suits was filed in state and federal courts over many years, and the case attracted high-profile representation on both sides. The dispute also produced collateral controversies: one prominent expert witness for the plaintiffs was later found to have falsified research on the drug's teratogenic effects and was removed from the medical register in Australia.

The litigation's most durable legal legacy came from a related challenge to the admission of expert evidence. The resulting Supreme Court decision, Daubert v. Merrell Dow Pharmaceuticals, established the standard federal courts use to evaluate the admissibility of expert testimony, replacing the older Frye formulation.

Outcome

Bendectin was withdrawn from the U.S. market in 1983, which is how this record treats the matter's resolution: a market withdrawal rather than a single court judgment. The birth-defect litigation continued for decades after the withdrawal, and a federal district court dismissed a key 1998 challenge on summary judgment, although the record does not document a final global resolution of the remaining claims.

In a 1999 determination published in the Federal Register, the FDA concluded that Bendectin "was not withdrawn from the market for reasons of safety or effectiveness," per https://www.gpo.gov/fdsys/pkg/FR-1999-08-09/pdf/99-20362.pdf. The doxylamine-pyridoxine combination later returned to the U.S. market in 2013 under the brand name Diclegis, manufactured by a different company, after a new regulatory review of the same two ingredients.